ORYZON announces formal grant of key European patent for vafidemstat

 Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the European Patent Office (EPO) has now formally granted Oryzon’s European patent EP3661510B1, titled “Methods of treating behavior alterations” related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder (BPD) and schizophrenia. The granted claims cover the use of vafidemstat for the treatment of aggression and social withdrawal. 

This newly granted European patent, which covers 40 countries, will not expire until at least 2038, excluding any potential patent term extensions that may provide additional years of protection. Corresponding patents have also been granted in Australia, South Korea, Malaysia, and Russia, with further patent applications pending in other key markets.

 In addition to this European patent, Oryzon recently received an “intention to grant” communication from the EPO for another important European patent application related to vafidemstat, EP20712565.9, titled “Methods of treating borderline personality disorder”. Once granted, this patent will remain in force until at least 2040, also excluding potential patent term extensions that may provide additional protection. Oryzon has received similar intention to grant communications for corresponding patent applications in Japan and Mexico, with additional patent applications pending in other relevant countries.

 “Securing these patents is a key achievement for Oryzon, as they ensure extended market exclusivity for vafidemstat and solidify our position in the psychiatric treatment landscape”, said Neus Virgili, Oryzon’s Chief IP Officer.